"Diabetes is a wonderful affection, not very frequent among men, being a melting down of the flesh and limbs into urine. The patients never stop making water, but the flow is incessant, as if from the opening of acqueducts. The nature of the disease, then, is chronic, and it takes a long period to form; but the patient is short-lived, if the constitution of the disease be completely established; for the melting is rapid, the death speedy."-Aretaeus the Cappadocian,[81-138]
Pfizer is planning to launch a program by which it monitors the effect of drug Exubera. Exubera is an inhaled insulin drug produced by Sanofi, Sanofi is a partner of Pfizer and there are controversies over plans of Pfizer planning to buy Sanofi. Doogan commented "We are in discussions with Sanofi about how the compound will get managed into the future," Pfizer plans to start the program as soon as its new drug is approved for use. This new drug Exubera is being reviewed and examined by the FDA panel for its approval.
Insulin is secreted by pancreas. This hormone is the key to the way your body processes food because it helps maintain the proper level of a sugar (glucose) in your blood. Glucose is your body's fuel. Cells use glucose to produce energy to grow and function. Glucose is escorted by insulin through your bloodstream and insulin helps in unlocking cells to allow glucose to enter. In diabetes, lack of insulin or the resistance of your cells to insulin prevents the right amount of glucose from entering your cells. The unused glucose builds up in your blood, a condition called hyperglycemia.
This new drug Exubera is expected to sell more than $ 2 million a year, but concerns regarding the side effects of this new drug is under study. As this new drug requires proper monitoring to study the effect of the drug, Pfizer is planning to start its follow up program. The use of oral insulin could change the way the people were using insulin all these days.
"This is a new departure and, of course, safety must be a major agenda item," he told Reuters in a telephone interview during a visit to Britain. "We have, I believe, a compelling approach to how we are going to evaluate patients in the post-approval world and, of course, we are going to be agreeing that with the regulatory authorities ... I don't think you will find us resistant."